![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
20
Glaxosmithkline Research & Development Limited London Gb, based in United Kingdom, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Mupirocin, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 2010-146 - Rev 01
This Chemical Type CEP, issued on October 02, 2017, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 1450 associated with this CEP further emphasizes